Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1962 5
1963 4
1964 3
1965 6
1966 6
1967 5
1968 4
1969 5
1970 1
1971 2
1973 3
1974 2
1975 2
1976 5
1977 4
1978 4
1979 6
1980 6
1981 2
1982 7
1983 9
1984 8
1985 10
1986 18
1987 8
1988 15
1989 12
1990 6
1991 17
1992 16
1993 31
1994 21
1995 25
1996 24
1997 24
1998 17
1999 30
2000 25
2001 26
2002 29
2003 26
2004 29
2005 34
2006 24
2007 35
2008 31
2009 30
2010 40
2011 65
2012 64
2013 42
2014 51
2015 39
2016 37
2017 59
2018 43
2019 55
2020 56
2021 69
2022 75
2023 68
2024 68
2025 69

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,442 results

Results by year

Filters applied: . Clear all
Page 1
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population.
Casadei-Gardini A, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Rimassa L, Presa J, Masi G, Yoo C, Lonardi S, Tovoli F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Pressiani T, Montes M, Vivaldi C, Soldà C, Piscaglia F, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Iavarone M, Di Costanzo G, Marra F, Scartozzi M, Tamburini E, Cabibbo G, Foschi FG, Silletta M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Burgio V, Persano M, Della Corte A, Ratti F, De Cobelli F, Aldrighetti L, Cascinu S, Cucchetti A. Casadei-Gardini A, et al. Among authors: nagano t. Eur J Cancer. 2023 Feb;180:9-20. doi: 10.1016/j.ejca.2022.11.017. Epub 2022 Nov 25. Eur J Cancer. 2023. PMID: 36527976 Clinical Trial.
Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthma.
Porsbjerg CM, Townend J, Bergeron C, Christoff GC, Katsoulotos GP, Larenas-Linnemann D, Tran TN, Al-Lehebi R, Bosnic-Anticevich SZ, Busby J, Hew M, Kostikas K, Papadopoulos NG, Pfeffer PE, Popov TA, Rhee CK, Sadatsafavi M, Tsai MJ, Ulrik CS, Al-Ahmad M, Altraja A, Beastall A, Bulathsinhala L, Carter V, Cosio BG, Fletton K, Hansen S, Heaney LG, Hubbard RB, Kuna P, Murray RB, Nagano T, Pini L, Cano Rosales DJ, Schleich F, Wechsler ME, Amaral R, Bourdin A, Brusselle GG, Chen W, Chung LP, Denton E, Fonseca JA, Hoyte F, Jackson DJ, Katial R, Kirenga BJ, Koh MS, Ławkiedraj A, Lehtimäki L, Liew MF, Mahboub B, Martin N, Menzies-Gow AN, Pang PH, Papaioannou AI, Patel PH, Perez-De-Llano L, Peters MJ, Ricciardi L, Rodríguez-Cáceres B, Solarte I, Tay TR, Torres-Duque CA, Wang E, Zappa M, Abisheganaden J, Assing KD, Costello RW, Gibson PG, Heffler E, Máspero J, Nicola S, Perng Steve DW, Puggioni F, Salvi S, Sheu CC, Sirena C, Taillé C, Tan TL, Bjermer L, Canonica GW, Iwanaga T, Jiménez-Maldonado L, Taube C, Brussino L, Price DB. Porsbjerg CM, et al. Among authors: nagano t. Front Immunol. 2024 Apr 19;15:1361891. doi: 10.3389/fimmu.2024.1361891. eCollection 2024. Front Immunol. 2024. PMID: 38711495 Free PMC article.
Efficacy of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma in immunotherapy era clinical practice.
Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ohama H, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Nishikawa H, Imai M, Aoki T, Ochi H, Tada F, Nakamura S, Nakamura Y, Nouso K, Morishita A, Itokawa N, Okubo T, Arai T, Tsutsui A, Nagano T, Tanaka K, Tanaka H, Koshiyama Y, Kanayama Y, Noritake H, Enomoto H, Kaibori M, Hiasa Y, Kudo M, Kumada T; RELPEC Group and HCC 48 Group. Hiraoka A, et al. Among authors: nagano t. Hepatol Res. 2025 Mar;55(3):444-453. doi: 10.1111/hepr.14136. Epub 2024 Nov 11. Hepatol Res. 2025. PMID: 39526824
Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial.
Kakihana Y, Nishida O, Taniguchi T, Okajima M, Morimatsu H, Ogura H, Yamada Y, Nagano T, Morishima E, Matsuda N; J-Land 3S Study Group. Kakihana Y, et al. Among authors: nagano t. Lancet Respir Med. 2020 Sep;8(9):863-872. doi: 10.1016/S2213-2600(20)30037-0. Epub 2020 Mar 31. Lancet Respir Med. 2020. PMID: 32243865 Clinical Trial.
Mitochondrial Dysfunction in Pulmonary Hypertension.
Ryanto GRT, Suraya R, Nagano T. Ryanto GRT, et al. Among authors: nagano t. Antioxidants (Basel). 2023 Feb 3;12(2):372. doi: 10.3390/antiox12020372. Antioxidants (Basel). 2023. PMID: 36829931 Free PMC article. Review.
Novel cancer therapy targeting microbiome.
Nagano T, Otoshi T, Hazama D, Kiriu T, Umezawa K, Katsurada N, Nishimura Y. Nagano T, et al. Onco Targets Ther. 2019 May 13;12:3619-3624. doi: 10.2147/OTT.S207546. eCollection 2019. Onco Targets Ther. 2019. PMID: 31190864 Free PMC article. Review.
Efficacy and safety of switching to bilastine, an H1-antihistamine, in patients with refractory chronic spontaneous urticaria (H1-SWITCH): a multicenter, open-label, randomized, parallel-group comparative study.
Fukunaga A, Kakei Y, Murakami S, Kan Y, Masuda K, Jinnin M, Washio K, Amano H, Nagano T, Yamamoto A, Otsuka T, Takahagi S, Takenaka M, Ishiguro N, Hayama K, Inomata N, Nakagawa Y, Sugiyama A, Hide M. Fukunaga A, et al. Among authors: nagano t. Front Immunol. 2024 Sep 16;15:1441478. doi: 10.3389/fimmu.2024.1441478. eCollection 2024. Front Immunol. 2024. PMID: 39351222 Free PMC article. Clinical Trial.
Possible Biomarkers for Cancer Immunotherapy.
Otoshi T, Nagano T, Tachihara M, Nishimura Y. Otoshi T, et al. Among authors: nagano t. Cancers (Basel). 2019 Jul 3;11(7):935. doi: 10.3390/cancers11070935. Cancers (Basel). 2019. PMID: 31277279 Free PMC article. Review.
1,442 results